HLS Swaps a Cash Cow for a Franchise — and Mails the Bill With the Guidance
NILEMDO's ramp and the Bayer heart-failure deal are real, but a lower-half EBITDA guide and Clozaril's patient-versus-sales gap show what the pivot costs
HLS.TO · Earnings Call · 2026-11-12
The Franchise Argument Is No Longer a Promise
For two years HLS Therapeutics has been telling investors that the bempedoic-acid franchise would eventually carry a business built on a single, aging, high-margin antipsychotic. This is the quarter where the arithmetic started to work. Cardiovascular net sales rose roughly 21% year-over-year in local currency, NILEMDO — in only its second full quarter — did more than CAD 800,000, up 91% sequentially, and, critically, the cardiovascular portfolio flipped from break-even in the first half to a $0.7 million direct brand contribution. That last number is the whole thesis in one line: the commercial infrastructure is already paid for, so incremental revenue drops through. “The story this quarter is execution in driving our cardiovascular portfolio forward, forging a clear path to accelerated revenue and adjusted EBITDA growth in 2027 and beyond.” — Craig Millian, Chief Executive Officer · 2026-11-12 The launch metrics support the rhetoric. Brian Walsh put “1,700 new patient starts in the quarter through end of September, and that's up 2,900 year-to-date” — Brian Walsh, Chief Operating Officer · 2026-11-12 — running at more than 3x the pace of Vascepa's equivalent launch window. Private payer agreements now cover over 80% of privately insured Canadians, mostly unrestricted, and management is explicit that only about one in five targeted prescribers has written a script at all. The opportunity to expand prescriber breadth and then depth is the single largest lever left, and it is a sales-force problem, not a clinical one. What is new this quarter is the vocabulary. Heart failure did not appear in HLS's curated themes until now; it arrives via VERQUVO, the Bayer partnership announced November 3. The structure matters more than the molecule: HLS books net sales and pays a royalty plus milestones, Bayer retains the authorization, and the initial spend is "modest and stage-gated." Peak sales were pegged at $5-10 million — not transformative — but the strategic read is that HLS is now a credible Canadian commercialization partner beyond lipids, which is precisely the pitch it will need for the next deal.The Guidance Tell
Here is where the story gets less comfortable. Revenue guidance was refined to roughly the midpoint of $56-60 million, but adjusted EBITDA was pushed to the lower half of $18.5-21 million. Management gave two reasons, and the CFO's split is the most honest line on the call: “It's a bit of a combination that order of magnitude, half of it related to spend, half of it related to the product mix.” — John Hanna, Chief Financial Officer · 2026-11-12 The mix half is structural and will not reverse: U.S. Clozaril, described as "extremely high margin," came in weaker in the back half than planned, so each dollar of cardiovascular revenue replaces a dollar that was more profitable. That is the price of diversification, and investors should assume it persists. The spend half is more interesting, because three months ago the same team was telling analysts the opposite. In August, the CFO agreed Q2 was “likely the peak of the 4 quarters” — John Hanna, Chief Financial Officer · 2026-08-12, and the CEO described the company as “holding the line on the side” — Craig Stuart Millian, Chief Executive Officer · 2026-08-12. Now there is incremental Q4 and first-half-2027 investment for the launch of NEXLIZET, a rebuilt patient support program, and a heavier presence at the Canadian Cardiovascular Congress. To be fair, the CEO pre-empted the criticism with a reasonable argument — “The last thing we want to do is, for the sake of saving a few hundred thousand dollars, slow down that growth.” — Craig Millian, Chief Executive Officer · 2026-11-12 A few hundred thousand dollars is genuinely small against a CAD 50-100 million peak-sales opportunity. But the pattern of "peak spend" followed by more spend is exactly the pattern that erodes credibility in micro-cap pharma, and it lands in the same quarter that the margin mix quietly deteriorates. Equally telling is what management stopped emphasizing. Vascepa was last quarter's headline keyword — a top gainer with the strongest momentum in the company's own theme history — and this quarter it does not appear in the top 30 at all, despite 8% local-currency growth and 14% unit growth. Business development, ranked third last quarter, has likewise fallen out of the theme list even as the company announced a deal. Payer mix, a recurring analytical concern, is gone. The narrative has consolidated around the franchise and its catalysts, and the older, messier businesses have been pushed to the perimeter.The Clozaril Question
Clozaril still funds everything — $6.3 million of direct brand contribution in the quarter, $18.7 million year-to-date, against $0.7 million from cardiovascular. But the framing changed. Last quarter's theme was the "Clozaril patient base" and retaining branded share; this quarter the keyword that survived is decline in Clozaril. Canada net sales fell 2.6% in local currency, U.S. sales were $2.8 million and flat, and U.S. is down 6.5% year-to-date after the REMS requirement disappeared and prescriptions drifted to retail pharmacies where generic switching is easier. The defence is the patient growth story — eight consecutive months of sequential gains nationally. But analyst David Martin pressed precisely the right point, and the answer was revealing:So the patient base is recovering off a trough the company created last year via Ontario competitive pressure, while sales still lag because the geographic mix shifts gross-to-net and hospital ordering in Ontario is lumpy. Management was candid that patient growth and ex-factory sales will not track quarter to quarter. Investors should hold them to that: if the patient line keeps rising for another two quarters without sales following, the "leading indicator" framing stops being an explanation and starts being an alibi.We do have, I think, 8 consecutive months of sequential patient growth, but still not quite back to where we were at the peak in 2025.